Compare BLDR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | BIO |
|---|---|---|
| Founded | 1998 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | RETAIL: Building Materials | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.9B |
| IPO Year | 2005 | N/A |
| Metric | BLDR | BIO |
|---|---|---|
| Price | $81.12 | $282.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 4 |
| Target Price | $121.76 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 2.2M | 330.1K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $0.71 | $2.74 |
| Revenue Next Year | $4.52 | $3.20 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.10 | $228.40 |
| 52 Week High | $151.03 | $343.12 |
| Indicator | BLDR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 45.45 |
| Support Level | $78.25 | $256.85 |
| Resistance Level | $130.47 | $288.48 |
| Average True Range (ATR) | 3.74 | 8.38 |
| MACD | 0.78 | -2.62 |
| Stochastic Oscillator | 81.27 | 6.17 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.